0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Histaminergic Regulation of Prolactin Secretion: Involvement of Tuberoinfundibular Dopaminergic Neurons

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          It has been shown that histamine (HA) stimulates prolactin (PRL) secretion via H<sub>2</sub> receptors following intra-cerebroventricular infusion and via Hi receptors following systemic (intra-arterial) infusion. Since the effect of HA appears to be exerted at a suprapituitary level, we investigated the involvement of the tuberoinfundibular dopaminergic (TIDA) system in HA-induced PRL secretion in urethane-anesthetized male rats. HA infused intracerebroventricularly (30 µg) or intra-arterially (420 µg) decreased the dopamine (DA) concentration in pituitary portal blood by 30 and 23%, respectively. Blockade of DA receptors by pimozide did not prevent the stimulation of PRL secretion induced by intracere-broventricular infusion of HA or the H<sub>2</sub> receptor agonist dimaprit. Furthermore, during DA receptor blockade intracere-broventricular infusion of the H<sub>1</sub> receptor agonist 2-thiazolylethylamine inhibited PRL secretion. In contrast, pimozide prevented the stimulation of PRL secretion induced by intra-arterial infusion of HA and the H<sub>1</sub> receptor agonist 2-thiazolylethylamine. In fact, under these conditions intra-arterial infusion of HA or the H<sub>2</sub>-receptor agonist dimaprit inhibited PRL secretion. During treatment with α-methyl-p-tyrosine, which reduced the hypothalamic DA content by 50%, HA infused intracerebroventricularly stimulated PRL secretion, while HA infused intra-arterially inhibited the secretion, which is in accordance with the results obtained during pimozide treatment. Cholinergic blockade by atropine did not prevent the HA-induced PRL release, exluding the possibility that the observed effect of pimozide is due to its anticholinergic property. We suggest that intracerebroventricular infusion of HA by activation of H<sub>2</sub> receptors may stimulate PRL secretion partly via inhibition of the TIDA system and partly via other mechanisms. Furthermore, by activation of H<sub>1</sub> receptors, intracerebroventricularly infused HA seems to inhibit PRL secretion by a DA-independent mechanism. In contrast, intra-arterial infusion of HA may by activation of H<sub>1</sub> receptors stimulate PRL secretion preferentially via inhibition of the TIDA system, while the H<sub>2</sub> receptor mediated PRL-inhibiting effect of intra-arterially infused HA may be related to other mechanisms.

          Related collections

          Author and article information

          Journal
          NEN
          Neuroendocrinology
          10.1159/issn.0028-3835
          Neuroendocrinology
          S. Karger AG
          0028-3835
          1423-0194
          1988
          1988
          02 April 2008
          : 48
          : 2
          : 167-173
          Affiliations
          Institute of Medical Physiology C, Panum Institute, University of Copenhagen, Denmark
          Article
          125005 Neuroendocrinology 1988;48:167–173
          10.1159/000125005
          2975768
          © 1988 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 7
          Categories
          Original Paper

          Comments

          Comment on this article